Published in J Urol on December 01, 2009
Management of renal collecting duct carcinoma: a systematic review and the McMaster experience. Curr Oncol (2013) 1.23
Non-clear cell renal cancer: disease-based management and opportunities for targeted therapeutic approaches. Semin Oncol (2013) 0.89
Collecting duct carcinomas represent a unique tumor entity based on genetic alterations. PLoS One (2013) 0.86
Systemic therapy for metastatic renal cell carcinoma: a review and update. Rev Urol (2012) 0.85
Collecting duct carcinoma of the kidney is associated with CDKN2A deletion and SLC family gene up-regulation. Oncotarget (2016) 0.83
Renal collecting duct carcinoma with extensive coagulative necrosis mimicking anemic infarct: report of a case and the literature review. Diagn Pathol (2013) 0.81
Editorial comment. J Urol (2009) 0.77
Collecting (Bellini) duct carcinoma: A clinical study of a rare tumour and review of the literature. Can Urol Assoc J (2015) 0.77
Reliable assessment of the effects of treatment on mortality and major morbidity, II: observational studies. Lancet (2001) 3.71
Collecting duct renal cell carcinoma: a matched analysis of 41 cases. Eur Urol (2007) 2.30
Collecting duct (Bellini duct) renal cell carcinoma: a nationwide survey in Japan. J Urol (2006) 1.78
Low-grade collecting duct carcinoma of the kidney: report of 13 cases of low-grade mucinous tubulocystic renal carcinoma of possible collecting duct origin. Urology (1997) 1.63
Collecting duct carcinoma of kidney. Semin Diagn Pathol (1998) 1.49
Collecting duct renal cell carcinoma: clinical study of a rare tumor. J Urol (2002) 1.31
Collecting duct carcinoma of the kidney: CT and pathologic correlation. Eur J Radiol (2005) 1.20
Collecting duct carcinoma of the kidney. Br J Urol (1993) 1.18
Collecting duct carcinoma of the kidney. Hum Pathol (1990) 1.17
Active chemotherapy for collecting duct carcinoma of the kidney: a case report and review of the literature. Cancer (2002) 1.14
Collecting duct carcinoma of the kidney: an immunohistochemical evaluation of the use of antibodies for differential diagnosis. Hum Pathol (2008) 1.11
Collecting duct carcinoma of the kidney: an immunohistochemical study of 11 cases. BMC Urol (2004) 1.05
Collecting duct renal cell carcinoma: two different clinical stages, two different clinical outcomes. Urol Int (2008) 0.96
Collecting duct carcinoma of the kidney: a case report and review of the literature. J Urol (1992) 0.87
Bellini duct (collecting duct) carcinoma of the kidney. Urology (1996) 0.85
Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A (2008) 33.65
Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. Cancer Res (2007) 5.97
Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol (2007) 5.23
Follow-up for Clinically Localized Renal Neoplasms: AUA Guideline. J Urol (2013) 2.76
Persistent intraprostatic androgen concentrations after medical castration in healthy men. J Clin Endocrinol Metab (2006) 2.57
Evaluation of the 8q24 prostate cancer risk locus and MYC expression. Cancer Res (2009) 2.54
Circumcision and the risk of prostate cancer. Cancer (2012) 2.48
SELDI-TOF MS whole serum proteomic profiling with IMAC surface does not reliably detect prostate cancer. Clin Chem (2007) 2.38
Castration-resistant prostate cancer: AUA Guideline. J Urol (2013) 2.36
Post-transcriptional generation of miRNA variants by multiple nucleotidyl transferases contributes to miRNA transcriptome complexity. Genome Res (2011) 2.34
Prostate cancer in men using testosterone supplementation. J Urol (2005) 2.12
The association between extent of lymphadenectomy and survival among patients with lymph node metastases undergoing radical cystectomy. Cancer (2008) 1.94
Positive surgical margins at radical prostatectomy predict prostate cancer specific mortality. J Urol (2010) 1.86
Clinical utility of five genetic variants for predicting prostate cancer risk and mortality. Prostate (2009) 1.83
Incidence of primary urethral carcinoma in the United States. Urology (2006) 1.78
Disseminated tumor cells in prostate cancer patients after radical prostatectomy and without evidence of disease predicts biochemical recurrence. Clin Cancer Res (2009) 1.69
Phase III prevention trial of fenretinide in patients with resected non-muscle-invasive bladder cancer. Clin Cancer Res (2008) 1.68
Differences in survival among patients with urachal and nonurachal adenocarcinomas of the bladder. Cancer (2006) 1.67
Using the epigenetic field defect to detect prostate cancer in biopsy negative patients. J Urol (2012) 1.60
Influence of publication of US and European prostate cancer screening trials on PSA testing practices. J Natl Cancer Inst (2011) 1.58
Male pattern baldness and prostate cancer risk in a population-based case-control study. Cancer Epidemiol (2010) 1.57
Expression of SLCO transport genes in castration-resistant prostate cancer and impact of genetic variation in SLCO1B3 and SLCO2B1 on prostate cancer outcomes. Cancer Epidemiol Biomarkers Prev (2011) 1.51
Obesity is associated with increased risks of prostate cancer metastasis and death after initial cancer diagnosis in middle-aged men. Cancer (2007) 1.47
Canary Prostate Active Surveillance Study: design of a multi-institutional active surveillance cohort and biorepository. Urology (2009) 1.46
Differences in survival among patients with sarcomatoid carcinoma, carcinosarcoma and urothelial carcinoma of the bladder. J Urol (2007) 1.42
Ductal adenocarcinoma of the prostate: increased mortality risk and decreased serum prostate specific antigen. J Urol (2010) 1.36
Serum steroid and sex hormone-binding globulin concentrations and the risk of incident benign prostatic hyperplasia: results from the prostate cancer prevention trial. Am J Epidemiol (2008) 1.34
A multi-institutional matched-control analysis of adjuvant and salvage postoperative radiation therapy for pT3-4N0 prostate cancer. Urology (2008) 1.32
Cigarette smoking and prostate cancer-specific mortality following diagnosis in middle-aged men. Cancer Causes Control (2007) 1.30
Prostate cancer mortality following active surveillance versus immediate radical prostatectomy. Clin Cancer Res (2012) 1.25
Tertiary Gleason pattern 5 in Gleason 7 prostate cancer predicts pathological stage and biochemical recurrence. J Urol (2008) 1.23
Effect of medical castration on CD4+ CD25+ T cells, CD8+ T cell IFN-gamma expression, and NK cells: a physiological role for testosterone and/or its metabolites. Am J Physiol Endocrinol Metab (2005) 1.21
Vitamin D pathway gene variants and prostate cancer prognosis. Prostate (2010) 1.20
Targeted androgen pathway suppression in localized prostate cancer: a pilot study. J Clin Oncol (2013) 1.14
Association of symptomatic benign prostatic hyperplasia and prostate cancer: results from the prostate cancer prevention trial. Am J Epidemiol (2011) 1.12
Biomarkers of systemic inflammation and risk of incident, symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. Am J Epidemiol (2010) 1.11
Testicular cancer. J Natl Compr Canc Netw (2012) 1.11
Primary scrotal cancer: disease characteristics and increasing incidence. Urology (2008) 1.09
Differential gene expression in benign prostate epithelium of men with and without prostate cancer: evidence for a prostate cancer field effect. Clin Cancer Res (2010) 1.09
The Personal Patient Profile-Prostate decision support for men with localized prostate cancer: a multi-center randomized trial. Urol Oncol (2011) 1.08
Erectile dysfunction after radical prostatectomy: hemodynamic profiles and their correlation with the recovery of erectile function. J Urol (2002) 1.07
Kidney cancer. J Natl Compr Canc Netw (2011) 1.06
Dihydrotestosterone administration does not increase intraprostatic androgen concentrations or alter prostate androgen action in healthy men: a randomized-controlled trial. J Clin Endocrinol Metab (2010) 1.04
Evidence that the human gene for prostate short-chain dehydrogenase/reductase (PSDR1) encodes a novel retinal reductase (RalR1). J Biol Chem (2002) 1.03
Contemporary grading for prostate cancer: implications for patient care. Eur Urol (2012) 1.03
What happens after an elevated PSA test: the experience of 13,591 veterans. J Gen Intern Med (2010) 0.99
Polymorphisms in the glutathione S-transferase M1, T1, and P1 genes and prostate cancer prognosis. Prostate (2006) 0.99
Incidence of testicular germ cell cancers in U.S. children: SEER program experience 1973 to 2000. Urology (2006) 0.98
Kidney cancer, version 2.2014. J Natl Compr Canc Netw (2014) 0.98
The basic biochemistry and molecular events of hormone therapy. Curr Urol Rep (2007) 0.96
The effect of demographic and clinical factors on the relationship between BMI and PSA levels. Prostate (2011) 0.95
Effects of screening on radical prostatectomy efficacy: the prostate cancer intervention versus observation trial. J Natl Cancer Inst (2013) 0.95
CYP17 polymorphisms and prostate cancer outcomes. Prostate (2010) 0.95
Response of the insulin-like growth factor (IGF) system to IGF-IR inhibition and androgen deprivation in a neoadjuvant prostate cancer trial: effects of obesity and androgen deprivation. J Clin Endocrinol Metab (2013) 0.93
Hospital-level variation in the quality of urologic cancer surgery. Cancer (2011) 0.92
Intermittent androgen deprivation: clinical experience and practical applications. Urol Clin North Am (2006) 0.91
Trends in renal cancer surgery and patient provider characteristics associated with partial nephrectomy in the United States. Urol Oncol (2007) 0.90
A model for the design and construction of a resource for the validation of prognostic prostate cancer biomarkers: the Canary Prostate Cancer Tissue Microarray. Adv Anat Pathol (2013) 0.90
Role of post-chemotherapy surgery in germ cell tumors. Urol Clin North Am (2007) 0.89
Serum adiponectin, C-peptide and leptin and risk of symptomatic benign prostatic hyperplasia: results from the Prostate Cancer Prevention Trial. Prostate (2009) 0.89
Tumor lysis syndrome in a patient with metastatic, androgen independent prostate cancer. Int J Urol (2005) 0.89
Association of hepsin gene variants with prostate cancer risk and prognosis. Prostate (2010) 0.88
PMN and anti-tumor immunity--the case of bladder cancer immunotherapy. Semin Cancer Biol (2013) 0.88
New and novel markers for prostate cancer detection. Curr Urol Rep (2009) 0.86
Testicular Cancer, Version 2.2015. J Natl Compr Canc Netw (2015) 0.86
Correlation between selenium concentrations and glutathione peroxidase activity in serum and human prostate tissue. Prostate (2009) 0.85
Advanced clinical states in prostate cancer. Urol Clin North Am (2012) 0.84
Statins and the risk of cancer. JAMA (2006) 0.84
AMACR polymorphisms, dietary intake of red meat and dairy and prostate cancer risk. Prostate (2010) 0.84
Predictors of upper tract urothelial cell carcinoma after primary bladder cancer: a population based analysis. J Urol (2009) 0.84
Management of clinical stage I nonseminomatous germ cell tumors. Expert Rev Anticancer Ther (2014) 0.83
Prostate cancer mortality in relation to screening by prostate-specific antigen testing and digital rectal examination: a population-based study in middle-aged men. Cancer Causes Control (2007) 0.83
Oxidative DNA damage in the prostate may predispose men to a higher risk of prostate cancer. Transl Oncol (2009) 0.82
Active surveillance for prostate cancer: the role of the pathologist. Pathology (2015) 0.82
Androgen receptor CAG repeat length is not associated with the risk of incident symptomatic benign prostatic hyperplasia: results from the Prostate Cancer Prevention Trial. Prostate (2010) 0.82
Prevalence of low testosterone and predisposing risk factors in men with type 1 diabetes mellitus: findings from the DCCT/EDIC. J Clin Endocrinol Metab (2014) 0.81
Prognostic value of combined "triple"-reverse transcription-PCR analysis for prostate-specific antigen, human kallikrein 2, and prostate-specific membrane antigen mRNA in peripheral blood and lymph nodes of prostate cancer patients. Clin Cancer Res (2004) 0.81
Consensus statement with recommendations on active surveillance inclusion criteria and definition of progression in men with localized prostate cancer: the critical role of the pathologist. Virchows Arch (2014) 0.81
Practical guide to the use of abiraterone in castration resistant prostate cancer. Can J Urol (2014) 0.80
Impact of male hormonal contraception on prostate androgens and androgen action in healthy men: a randomized, controlled trial. J Clin Endocrinol Metab (2012) 0.80
Genetics: Prostate cancer risk stratification by genotype and PSA. Nat Rev Urol (2009) 0.80
A study of caloric restriction versus standard diet in overweight men with newly diagnosed prostate cancer: a randomized controlled trial. Prostate (2013) 0.79
A dietary intervention to elicit rapid and complex dietary changes for studies investigating the effects of diet on tissues collected during invasive surgical procedures. J Am Diet Assoc (2009) 0.79
Editorial comment on "Treatment of nonretroperitoneal residual germ cell tumor masses". Urol Oncol (2005) 0.78
A preliminary exploration of the feasibility of offering men information about potential prostate cancer treatment options before they know their biopsy results. BMC Med Inform Decis Mak (2013) 0.78
Clinical roundtable monograph: new and emerging treatments for advanced prostate cancer. Clin Adv Hematol Oncol (2011) 0.77
Current status of focal primary therapy for prostate cancer. Urol Oncol (2012) 0.77
Neobladders and continent catheterizable stomas for the bladder cancer survivor. Curr Opin Urol (2014) 0.76
Positive surgical margins at radical prostatectomy: Population-based averages within PSA and Gleason strata. Can Urol Assoc J (2013) 0.76
Prostate cancer that is within 0.1 mm of the surgical margin of a radical prostatectomy predicts greater likelihood of recurrence. Am J Surg Pathol (2014) 0.75
Differences in Upgrading of Prostate Cancer in Prostatectomies between Community and Academic Practices. Adv Urol (2013) 0.75
Sequencing therapy in advanced prostate cancer: focus on sipuleucel-T. Expert Rev Anticancer Ther (2014) 0.75
Editorial comment on: marked gene transcript level alterations occur early during radical prostatectomy. Eur Urol (2008) 0.75
Microarray analysis and tumor classification. N Engl J Med (2006) 0.75
Reply to circumcision unlikely to be associated with prostate cancer risk. Cancer (2012) 0.75
Does the who and how of surgery in bladder cancer matter? J Clin Oncol (2004) 0.75
The increasing role of CAM in prostate cancer. JAAPA (2004) 0.75